We are live on ! Find out more
BCLI

BRAINSTORM CELL THERAPUTC
BCLI

Delisted

BCLI was delisted on the 17th of July, 2025.

Back to rankings

21 hedge funds and large institutions have $10.7M invested in BRAINSTORM CELL THERAPUTC in 2015 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 5 increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

2,095% more capital invested

Capital invested by funds: $488K → $10.7M (+$10.2M)

500% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 2

400% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 1

91% more funds holding

Funds holding: 11 → 21 (+10)

Holders
21
Holders Change
+10
Holders Change %
+90.91%
% of All Funds
0.56%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
12
Increased
5
Reduced
1
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
+$5.94M
2
PA
Perceptive Advisors
New York
+$1.69M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$1.36M
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$186K
5
TC
TFS Capital
Pennsylvania
+$174K

Top Sellers

Rank Fund Capital Flow
1
PNC Financial Services Group
PNC Financial Services Group
Pennsylvania
-$3K
2
VKH
Virtu KCG Holdings
New York
-$1.07K

BCLI Hedge Fund Activity: Q1 2015 in Review

21 of the 3,770 institutional investors tracked by Wall St. Rank reported a position in BRAINSTORM CELL THERAPUTC (BCLI) for Q1 2015, worth a combined $10.7M — up 2,095% from $488K a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new BCLI positions and 2 closed out — a net gain of 10 holders — while 5 added to existing stakes and 1 trimmed.

The largest buyer was Sabby Management, opening a new position worth an estimated $5.94M. The largest seller was PNC Financial Services Group, exiting entirely with an estimated $3K sold.

  • 21 institutional investors held BRAINSTORM CELL THERAPUTC (BCLI) as of Q1 2015, up from 11 in Q4 2014.
  • Funds reported $10.7M of BRAINSTORM CELL THERAPUTC stock for Q1 2015, up 2,095% quarter-over-quarter.
  • 12 funds opened new BRAINSTORM CELL THERAPUTC positions in Q1 2015 and 2 closed out, a net change of +10 holders.
  • The largest BRAINSTORM CELL THERAPUTC buyer in Q1 2015 was Sabby Management, an estimated $5.94M added.
  • The largest BRAINSTORM CELL THERAPUTC seller in Q1 2015 was PNC Financial Services Group, an estimated $3K sold.

Based on aggregated 13F filings for Q1 2015.